PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26378049-7	2015	Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing.	LTX-315	118-125	BCL2 apoptosis regulator	Homo sapiens	66-71
28920000-5	2017	LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315 represents a new approach to cancer immunotherapy, which has the potential as a novel immunotherapeutic agent.	LTX-315	0-7	high mobility group box 1	Rattus norvegicus	169-174
27082453-5	2016	This synergistic interaction between CTLA4 blockade and LTX-315 was reduced upon blockade of the beta-chain of the interleukin-2 receptor (CD122).	LTX-315	56-63	interleukin 2 receptor subunit beta	Homo sapiens	139-144
26962684-1	2016	LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.	LTX-315	0-7	BCL2 associated X, apoptosis regulator	Homo sapiens	126-129
26962684-1	2016	LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.	LTX-315	0-7	BCL2 antagonist/killer 1	Homo sapiens	130-134
26962684-5	2016	When injected into established cancers, LTX-315 caused a transiently hemorrhagic focal necrosis that was accompanied by massive release of HMGB1 (from close-to-all cancer cells), as well as caspase-3 activation in a fraction of the cells.	LTX-315	40-47	high mobility group box 1	Homo sapiens	139-144
26378049-7	2015	Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing.	LTX-315	118-125	BCL2 associated X, apoptosis regulator	Homo sapiens	80-83
26378049-7	2015	Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing.	LTX-315	118-125	BCL2 antagonist/killer 1	Homo sapiens	88-91
24676901-6	2014	LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1beta, IL6 and IL18 in vivo.	LTX-315	0-7	high mobility group box 1	Mus musculus	89-114
24676901-6	2014	LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1beta, IL6 and IL18 in vivo.	LTX-315	0-7	interleukin 1 beta	Mus musculus	201-223
24676901-6	2014	LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1beta, IL6 and IL18 in vivo.	LTX-315	0-7	interleukin 6	Mus musculus	225-228
24676901-6	2014	LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1beta, IL6 and IL18 in vivo.	LTX-315	0-7	interleukin 18	Mus musculus	233-237
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	166-173	beclin 1	Homo sapiens	27-35
34309113-0	2021	Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.	LTX-315	12-19	beclin 1	Homo sapiens	98-106
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	166-173	AKT serine/threonine kinase 1	Homo sapiens	69-72
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	166-173	mechanistic target of rapamycin kinase	Homo sapiens	79-83
34309113-0	2021	Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.	LTX-315	12-19	mechanistic target of rapamycin kinase	Homo sapiens	112-116
34309113-11	2021	CONCLUSION: LTX-315 can inhibit the resistance of OC cells to DDP in vitro and plays a role by regulating Beclin-1/phosphatidylinositol-3-kinase/mTOR signaling pathway.	LTX-315	12-19	beclin 1	Homo sapiens	106-114
34309113-9	2021	In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.	LTX-315	25-32	BCL2 apoptosis regulator	Homo sapiens	91-96
34309113-11	2021	CONCLUSION: LTX-315 can inhibit the resistance of OC cells to DDP in vitro and plays a role by regulating Beclin-1/phosphatidylinositol-3-kinase/mTOR signaling pathway.	LTX-315	12-19	mechanistic target of rapamycin kinase	Homo sapiens	145-149
34174350-3	2021	Here, we describe cRGD-functionalized chimaeric polymersomes (cRGD-CPs) as a robust systemic delivery vehicle for LTX-315, which in combination with CpG adjuvant and anti-PD-1 boost immunotherapy of malignant B16F10 melanoma in mice.	LTX-315	114-121	programmed cell death 1	Mus musculus	171-175
34309113-9	2021	In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.	LTX-315	25-32	caspase 3	Homo sapiens	169-178
34309113-9	2021	In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.	LTX-315	25-32	poly(ADP-ribose) polymerase 1	Homo sapiens	188-192
34309113-9	2021	In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.	LTX-315	25-32	BCL2 associated X, apoptosis regulator	Homo sapiens	197-200
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	10-17	beclin 1	Homo sapiens	27-35
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	10-17	AKT serine/threonine kinase 1	Homo sapiens	69-72
34309113-10	2021	Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels, whereas 3-MA could partially reverse the biological effects of LTX-315 on OC cells.	LTX-315	10-17	mechanistic target of rapamycin kinase	Homo sapiens	79-83
35288467-0	2022	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.	LTX-315	18-25	ATPase, class VI, type 11B	Mus musculus	83-89
35288467-0	2022	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.	LTX-315	18-25	CD274 antigen	Mus musculus	90-95
35288467-1	2022	BACKGROUND: LTX-315 is an oncolytic peptide deriving from bovine lactoferrin, with the ability to induce cancer immunogenic cell death.	LTX-315	12-19	lactotransferrin	Bos taurus	65-76
35288467-4	2022	This study aimed to demonstrate the potential effect and mechanism of LTX-315 in PD-L1 inhibition-induced anti-pancreatic cancer immunity.	LTX-315	70-77	CD274 antigen	Mus musculus	81-86
35288467-9	2022	RESULTS: LTX-315 treatment inhibited PD-L1 expression and enhanced lymphocyte infiltration in pancreatic tumors.	LTX-315	9-16	CD274 antigen	Mus musculus	37-42
35288467-14	2022	CONCLUSIONS: LTX-315 was first identified as a peptide drug inducing PD-L1 downregulation via ATP11B.	LTX-315	13-20	CD274 antigen	Mus musculus	69-74
35288467-14	2022	CONCLUSIONS: LTX-315 was first identified as a peptide drug inducing PD-L1 downregulation via ATP11B.	LTX-315	13-20	ATPase, class VI, type 11B	Mus musculus	94-100
35288467-15	2022	Therefore, LTX-315, or the development of ATP11B-targeting drugs, might improve the efficacy of cancer immunotherapy.	LTX-315	11-18	ATPase, class VI, type 11B	Mus musculus	42-48